Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F2CH
|
|||
| Former ID |
DNC000972
|
|||
| Drug Name |
Mutated growth hormone
|
|||
| Indication | Acromegaly [ICD-11: 5A60.0; ICD-10: E22.0; ICD-9: 253] | Investigative | [1] | |
| Company |
JCR Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Growth hormone-releasing hormone receptor (GHRHR) | Target Info | Agonist | [1] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | G alpha (s) signalling events | |||
| Glucagon-type ligand receptors | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.